Bloomberg Stock Movers
2026-07-15 · Hosted by — · Bloomberg / iHeartMedia
Executive Summary
Q2 earnings season continued with Johnson & Johnson beating top- and bottom-line estimates and modestly raising 2026 guidance, though shares dipped nearly 2% in the pre-market after a ~64% run-up over the past year. BlackRock posted a strong beat with $15.3 trillion in assets under management and a record first-half of $321 billion in net inflows, sending shares up over 3%. ASML lifted its annual sales forecast to around $50 billion and beat on both lines, also disclosing that Intel is using its most advanced chip-production machine. IBM, still reeling from its historic 25% plunge the prior day — its biggest drop on record dating back to at least the 1960s — showed early signs of stabilizing, bouncing about 1%.
Key Stories & Changes
1. Q2 Earnings Roundup: Healthcare, Asset Management, and Chip Equipment
JNJ: Johnson & Johnson — -2% (pre-market) — Beat top/bottom line; raised 2026 sales and profit guidance; pullback follows a ~64% one-year rally
BLK: BlackRock — +3%+ (pre-market) — Record first-half net inflows of $321B ($15.3T AUM); 8% growth in organic base fees
ASML: ASML — Beat on both lines — Raised annual sales forecast to ~$50B; Intel using its most advanced chip-production machine
IBM: IBM — +~1% (early bounce) — Stabilizing after historic ~25% drop, the biggest on record dating back to at least the 1960s
2. Johnson & Johnson Beats but Pulls Back on Valuation
J&J beat Q2 top- and bottom-line estimates and modestly raised full-year 2026 sales and profit guidance
Growth was driven by cancer, inflammatory disease, and treatment-resistant depression drugs
The company has been investing heavily in new drugs to offset revenue lost after losing exclusivity on a key drug last year
Despite the beat, shares fell nearly 2% in the pre-market, following a nearly 64% rally over the past year that outpaced peers Merck (+48%) and Eli Lilly (+49%)
J&J's results, reported ahead of competitors, are seen as a sector bellwether, suggesting drugmakers are thriving despite recent FDA turmoil and White House drug-pricing deals
3. BlackRock's Record Inflows
BlackRock posted $15.3 trillion in assets under management and a record first-half with $321 billion in net inflows, more than half arriving in Q2 alone
Inflows were broad-based across ETFs, private markets, active fixed income, and systematic equity strategies
Organic base fees grew 8%, reflecting investor preference for higher-fee products
Shares rose more than 3% in the pre-market on the beat
4. ASML Lifts Guidance on AI Chip Demand
ASML raised its annual sales forecast to around $50 billion, alongside a top- and bottom-line beat for the quarter
The company makes machines used to manufacture AI chips; demand remains strong despite machines costing over $400 million
Intel is now using ASML's most advanced chip-production machine
ASML is also investigating expanding capacity for its lower-cost "workhorse" machines used for both AI processors and high-bandwidth memory
5. IBM Attempts to Stabilize After Historic Plunge
IBM shares are bouncing about 1% after Monday's roughly 25% drop, the biggest decline on record dating back to at least the 1960s
The move followed preliminary results showing a miss, with the stock still "settling" and having recovered only a small fraction of the prior day's loss
Trends Identified
1. AI Infrastructure Demand Continues to Support Chip Equipment Makers
ASML's guidance raise and confirmation of Intel's adoption of its most advanced machine reinforce that capital spending on AI chip-manufacturing capacity remains robust even as other parts of the tech ecosystem (like IBM) show signs of stress — underscoring the bifurcation between AI-infrastructure-adjacent names and legacy enterprise software/hardware players.
2. Strong Earnings Beats Meeting Profit-Taking on Elevated Valuations
Both J&J and the broader pattern suggest that even solid earnings beats and raised guidance are being met with selling when a stock has already run up significantly (J&J's ~64% one-year gain), indicating investors are becoming more selective about paying up further even for fundamentally strong results. ---
Sentiment Analysis
Overall Market Sentiment: Cautiously Positive
Earnings beats across pharma, asset management, and chip equipment reinforced a generally constructive tone, tempered by valuation-driven profit-taking and lingering uncertainty around IBM's stabilization.
Risk Factors Highlighted
Valuation-driven pullbacks despite beats: J&J fell despite a beat and raised guidance, reflecting reduced tolerance for paying up after large prior rallies.
IBM recovery remains fragile: Only a modest ~1% bounce following the biggest one-day drop in company history signals lingering investor caution.
Pharma sector regulatory turbulence: J&J's results come against a backdrop of "recent turmoil at the FDA" and White House drug-pricing deals.
High capital costs for AI chip infrastructure: ASML's advanced machines cost over $400 million each, concentrating capacity investment among the largest chipmakers.
This episode was covered in today's [The Market Signal — 2026-07-15](https://marketsignal.beehiiv.com/p/the-market-signal-2026-07-15), a cross-source synthesis of multiple podcast reports.